ANCA (anti-neutrophil cytoplasmic) antibodies are associated with increased risk of interstitial lung disease (ILD), pulmonary embolism (PE) and overall mortality in patients with systemic sclerosis, an Australian study shows. ANCA antibodies should be tested at baseline in all scleroderma patients at diagnosis to identify those with worse prognosis who will require closer monitoring and follow-up, ...
3 reasons to test for ANCA in scleroderma patients
By Dennis Neuen
20 Feb 2019